Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM. Vogiatzi F, et al. Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364. Blood Adv. 2022. PMID: 35820018 Free PMC article.
The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: I-Methodology for the development of consensus practice guidelines.
Wilkinson JD, Allen U, Green M, Dipchand AI, Dharnidharka VR, Esquivel CO, Maecker-Kolhoff B, Preiksaitis J, Swerdlow SH, Webber SA; IPTA Pediatric PTLD Consensus Guidelines Conference. Wilkinson JD, et al. Pediatr Transplant. 2024 Feb;28(1):e14333. doi: 10.1111/petr.14333. Epub 2022 Nov 11. Pediatr Transplant. 2024. PMID: 36369733 Review.
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia.
Stanulla M, Schewe DM, Bornhauser B, Bourquin JP, Eckert C, Eberl W, Wolf S, Wolf J, Vogiatzi F, Bergmann AK, Cario G, Beier R, Sauer M, Kratz CP, Maecker-Kolhoff B. Stanulla M, et al. Ann Hematol. 2023 Mar;102(3):669-672. doi: 10.1007/s00277-023-05083-y. Epub 2023 Jan 18. Ann Hematol. 2023. PMID: 36651980 Free PMC article. No abstract available.
Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT.
Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T. Feucht J, et al. Blood. 2015 Mar 19;125(12):1986-94. doi: 10.1182/blood-2014-06-573725. Epub 2015 Jan 23. Blood. 2015. PMID: 25617426 Free article. Clinical Trial.
Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients.
Taj MM, Maecker-Kolhoff B, Ling R, Bomken S, Burkhardt B, Chiang AKS, Csoka M, Füreder A, Haouy S, Lazic J, Miakova N, Minard-Colin V, Turner SD, Uyttebroeck A, Attarbaschi A; European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL), the international Berlin-Frankfurt-Münster (i-BFM) Study Group. Taj MM, et al. Br J Haematol. 2021 Jun;193(6):1178-1184. doi: 10.1111/bjh.17398. Epub 2021 Mar 25. Br J Haematol. 2021. PMID: 33764500 Clinical Trial.
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
Knörr F, Zimmermann M, Attarbaschi A, Kabíčková E, Maecker-Kolhoff B, Ruf S, Kühnle I, Ebinger M, Garthe AK, Simonitsch-Klupp I, Oschlies I, Klapper W, Burkhardt B, Woessmann W. Knörr F, et al. Haematologica. 2021 Dec 1;106(12):3232-3235. doi: 10.3324/haematol.2021.278971. Haematologica. 2021. PMID: 34498443 Free PMC article. No abstract available.
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.
Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, Dave S, Tzankov A, Dugas M, Sandmann S, Fend F, Finger J, Mueller S, Gökbuget N, Haferlach T, Kern W, Hartmann W, Klapper W, Oschlies I, Richter J, Kontny U, Lutz M, Maecker-Kolhoff B, Ott G, Rosenwald A, Siebert R, von Stackelberg A, Strahm B, Woessmann W, Zimmermann M, Zapukhlyak M, Grau M, Lenz G. Burkhardt B, et al. Nat Commun. 2022 Jul 6;13(1):3881. doi: 10.1038/s41467-022-31355-8. Nat Commun. 2022. PMID: 35794096 Free PMC article.
Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S, Bonifacius A, Santamorena MM, Mausberg P, Stoll S, Döring M, Kalinke U, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Tischer-Zimmermann S, et al. Front Immunol. 2023 Mar 24;14:878953. doi: 10.3389/fimmu.2023.878953. eCollection 2023. Front Immunol. 2023. PMID: 37033971 Free PMC article.
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft HG, Arseniev L, Beier R, Beutel G, Cario G, Fröhlich B, Greil J, Hansmann L, Hasenkamp J, Höfs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kröger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt HC, Sala E, Sauer MG, Schmitt C, Schroers R, Steckel NK, Trappe RU, Verbeek M, Wolff D, Blasczyk R, Eiz-Vesper B, Maecker-Kolhoff B. Bonifacius A, et al. Among authors: maecker kolhoff b. J Clin Invest. 2023 Jun 15;133(12):e163548. doi: 10.1172/JCI163548. J Clin Invest. 2023. PMID: 37159273 Free PMC article.
89 results